Sarepta partners with StrideBio to enable viral gene therapy re-dosing

To enable repeat dosing of adeno-associated virus gene therapies, Sarepta is partnering with StrideBio to use the latter’s capsid technology in up to eight CNS and neuromuscular programs.

The immunogenicity of viral antigens limits the number of times a patient may receive any given gene therapy. StrideBio, which raised a $15.7 million series A in June 2018, is designing AAV capsids that can evade neutralizing antibodies (see “AAV Plasmid Company StrideBio Raises $15.7M Series A”)...